Synthesis of some N-hydroxycinnamamide and N-hydroxybenzamide Derivatives Bearing Amide Bonds Targeting HDAC
Main Article Content
Abstract
Recently, hydroxamic acid has attracted considerable interest because of its ability to inhibit a variety of metal-containing enzymes such as metalloproteases, lipoxygenases, histone deacetylases, and cancer cells. For example, hydroxamic acid derivatives (vorinostat, belinostat, givinostat, panobinostat) have been approved by the US FDA for the treatment of various cancers. Based on the N-hydroxycinnamamide and N-hydroxybenzamide framework, the study described and synthesized N-hydroxycinnamamide and N-hydroxybenzamide derivatives bearing amide bonds as histone deacetylases enzyme inhibitors. The structures of the compounds were determined through modern NMR spectroscopy. The compounds were then molecularly docked to the active site of the HDAC6 enzyme, the results showed that the compounds strongly bound to the zinc ion and key amino acids. These results suggest that the synthesized N-hydroxycinnamamide and N-hydroxybenzamide derivatives are potential molecular targeted therapy for HDAC positive cancer in the future.
Keywords:
Cancer, histone deacetylase, N-hydroxybenzamide, N-hydroxycinnamamide, molecular docking.
References
[1] E. M. Muri, M. J. Nieto, R. D. Sindelar, J. S. Williamson, Hydroxamic Acids as Pharmacological Agents, Current Medicinal Chemistry, Vol. 9, No. 17, 2002, pp. 1631-1653.
[2] Y. Zhang, P. Yang, C. J. Chou, C. Liu, X. Wang, W. Xu, Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with An Indole-Containing Cap Group, ACS Medicinal Chemistry Letters, Vol 4, No. 2, 2013, pp. 235-238.
[3] H. Su, L. Yu, A. Nebbioso, V. Carafa, Y. Chen, L. Altucci, Q. You, Novel N-Hydroxybenzamide-Based HDAC Inhibitors with Branched CAP Group, Bioorganic and Medicinal Chemistry Letters, Vol. 19, No. 22, 2009, pp. 6284-6288.
[4] D. A. Rodrigues, G. A. Ferreira-Silva, A. C. Ferreira, R. A. Fernandes, et al., Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors, Journal of Medicinal Chemistry, Vol. 59, No. 2, 2016, pp. 655-670.
[5] X. Li, E. S. Inks, X. Li, J. Hou, C. J. Chou, J. Zhang, et al., Discovery of The First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity, Journal of Medicinal Chemistry, Vol. 57, No. 8, 2014, pp. 3324-3341.
[6] Y. Zhou, Y. Dun, H. Fu, L. Wang, X. Pan, X. Yang, H. Fang, Design, Synthesis, and Preliminary Bioactivity Evaluation of N‐Benzylpyrimidin‐2‐amine Derivatives as Novel Histone Deacetylase Inhibitor, Chemical Biology and Drug Design, Vol. 90, No. 5, 2017, pp. 936-942.
[7] S. M. L. Gantt, C. Decroos, M. S. Lee, et al., General Base-General Acid Catalysis in Human Histone Deacetylase 8, Biochemistry, Vol. 55, No. 5, 2016, pp. 820-832.
[8] Y. X. Huang, J. Zhao, Q. H. Song, et al., Virtual Screening and Experimental Validation of Novel Histone Deacetylase Inhibitors, BMC Pharmacology and Toxicology, Vol. 17, No. 1, 2016, pp. 1-14.
[9] Y. Li, E. Seto, HDACs and HDAC Inhibitors in Cancer Development and Therapy, Cold Spring Harbor Perspectives in Medicine, Vol. 6, No. 10, 2016, pp. a026831.
[10] J. E. Bolden, M. J. Peart, R. W. Johnstone, Anticancer Activities of Histone Deacetylase Inhibitors, Nature Reviews Drug Discovery, Vol. 5, No. 9, 2006, pp. 769-784.
[11] R. W. Johnstone, Histone-Deacetylase Inhibitors: Novel Drugs for Treatment of Cancer, Nature Reviews Drug Discovery, Vol. 1, No. 4, 2002, pp. 287-299.
[12] S. Grant, C. Easley, P. Kirkpatrick, Vorinostat, Nature Reviews Drug Discovery, Vol. 6, No. 1, 2007, pp. 21-22.
[13] R. M. Poole, Belinostat: First Global Approval, Drugs, Vol. 74, No. 13, 2014, pp. 1543-1554.
[14] K. P. G. Jones, Panobinostat: First Global Approval, Drugs, Vol. 75, No. 6, 2015, pp. 695-704.
[15] E. M. Bertino, G. A. Otterson, Romidepsin: A Novel Histone Deacetylase Inhibitor for Cancer, Expert Opinion on Investigational Drugs, Vol. 20, No. 8, 2011, pp. 1151-1158.
[16] F. Angeletti, G. Fossati, A. Pattarozzi, et al., Inhibition of Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells, Frontiers in Molecular Neuroscience, Vol. 9, 2016, pp. 107.
[17] E. Pontiki, D. H. Litina, Histone Deacetylase Inhibitors (HDACIs), Structure-Activity Relationships: History and New QSAR Perspectives, Medicinal Research Reviews, Vol. 32, No. 1, 2012, pp. 1-165.
[18] H. P. Nguyen, Q. D. Tran, C. Q. Nguyen, et al., Anti-Multiple Myeloma Potential of Resynthesized Belinostat Derivatives: An Experimental Study on Cytotoxic Activity, Drug Combination, and Docking Studies, RSC Advances, Vol. 12, No. 34, 2022, pp. 22108-22118.
[19] H. T. B. Bui, P. H. Nguyen, Q. M. Pham, et al., Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety, Molecules, Vol. 27, No. 7, 2022, pp. 2204.
[20] A. Mai, S. Massa, R. Pezzi, S. Valente, P. Loidl, G. Brosch, Synthesis and Biological Evaluation of 2-, 3-, and 4-Acylaminocinnamyl-N-hydroxyamides as Novel Synthetic HDAC Inhibitors, Medicinal Chemistry, Vol. 1, No. 3, 2005, pp. 245-254.
[21] Q. Lu, D. S. Wang, C. S. Chen, Y. D. Hu, C. S. Chen, Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors, Journal of Medicinal Chemistry, Vol. 48, No. 17, 2005, pp. 5530-5535.
[2] Y. Zhang, P. Yang, C. J. Chou, C. Liu, X. Wang, W. Xu, Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with An Indole-Containing Cap Group, ACS Medicinal Chemistry Letters, Vol 4, No. 2, 2013, pp. 235-238.
[3] H. Su, L. Yu, A. Nebbioso, V. Carafa, Y. Chen, L. Altucci, Q. You, Novel N-Hydroxybenzamide-Based HDAC Inhibitors with Branched CAP Group, Bioorganic and Medicinal Chemistry Letters, Vol. 19, No. 22, 2009, pp. 6284-6288.
[4] D. A. Rodrigues, G. A. Ferreira-Silva, A. C. Ferreira, R. A. Fernandes, et al., Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors, Journal of Medicinal Chemistry, Vol. 59, No. 2, 2016, pp. 655-670.
[5] X. Li, E. S. Inks, X. Li, J. Hou, C. J. Chou, J. Zhang, et al., Discovery of The First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity, Journal of Medicinal Chemistry, Vol. 57, No. 8, 2014, pp. 3324-3341.
[6] Y. Zhou, Y. Dun, H. Fu, L. Wang, X. Pan, X. Yang, H. Fang, Design, Synthesis, and Preliminary Bioactivity Evaluation of N‐Benzylpyrimidin‐2‐amine Derivatives as Novel Histone Deacetylase Inhibitor, Chemical Biology and Drug Design, Vol. 90, No. 5, 2017, pp. 936-942.
[7] S. M. L. Gantt, C. Decroos, M. S. Lee, et al., General Base-General Acid Catalysis in Human Histone Deacetylase 8, Biochemistry, Vol. 55, No. 5, 2016, pp. 820-832.
[8] Y. X. Huang, J. Zhao, Q. H. Song, et al., Virtual Screening and Experimental Validation of Novel Histone Deacetylase Inhibitors, BMC Pharmacology and Toxicology, Vol. 17, No. 1, 2016, pp. 1-14.
[9] Y. Li, E. Seto, HDACs and HDAC Inhibitors in Cancer Development and Therapy, Cold Spring Harbor Perspectives in Medicine, Vol. 6, No. 10, 2016, pp. a026831.
[10] J. E. Bolden, M. J. Peart, R. W. Johnstone, Anticancer Activities of Histone Deacetylase Inhibitors, Nature Reviews Drug Discovery, Vol. 5, No. 9, 2006, pp. 769-784.
[11] R. W. Johnstone, Histone-Deacetylase Inhibitors: Novel Drugs for Treatment of Cancer, Nature Reviews Drug Discovery, Vol. 1, No. 4, 2002, pp. 287-299.
[12] S. Grant, C. Easley, P. Kirkpatrick, Vorinostat, Nature Reviews Drug Discovery, Vol. 6, No. 1, 2007, pp. 21-22.
[13] R. M. Poole, Belinostat: First Global Approval, Drugs, Vol. 74, No. 13, 2014, pp. 1543-1554.
[14] K. P. G. Jones, Panobinostat: First Global Approval, Drugs, Vol. 75, No. 6, 2015, pp. 695-704.
[15] E. M. Bertino, G. A. Otterson, Romidepsin: A Novel Histone Deacetylase Inhibitor for Cancer, Expert Opinion on Investigational Drugs, Vol. 20, No. 8, 2011, pp. 1151-1158.
[16] F. Angeletti, G. Fossati, A. Pattarozzi, et al., Inhibition of Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells, Frontiers in Molecular Neuroscience, Vol. 9, 2016, pp. 107.
[17] E. Pontiki, D. H. Litina, Histone Deacetylase Inhibitors (HDACIs), Structure-Activity Relationships: History and New QSAR Perspectives, Medicinal Research Reviews, Vol. 32, No. 1, 2012, pp. 1-165.
[18] H. P. Nguyen, Q. D. Tran, C. Q. Nguyen, et al., Anti-Multiple Myeloma Potential of Resynthesized Belinostat Derivatives: An Experimental Study on Cytotoxic Activity, Drug Combination, and Docking Studies, RSC Advances, Vol. 12, No. 34, 2022, pp. 22108-22118.
[19] H. T. B. Bui, P. H. Nguyen, Q. M. Pham, et al., Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety, Molecules, Vol. 27, No. 7, 2022, pp. 2204.
[20] A. Mai, S. Massa, R. Pezzi, S. Valente, P. Loidl, G. Brosch, Synthesis and Biological Evaluation of 2-, 3-, and 4-Acylaminocinnamyl-N-hydroxyamides as Novel Synthetic HDAC Inhibitors, Medicinal Chemistry, Vol. 1, No. 3, 2005, pp. 245-254.
[21] Q. Lu, D. S. Wang, C. S. Chen, Y. D. Hu, C. S. Chen, Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors, Journal of Medicinal Chemistry, Vol. 48, No. 17, 2005, pp. 5530-5535.